STAT News

STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit

Europe pulls Tavneos over trial integrity concerns, pricing concerns over AstraZeneca's hypertension drug, and more biotech news from The Readout

By STAT News

1 min read
STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit
STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights